Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Pfizer Inc.. A complete text table follows the diagram.
Primary care remains the largest franchise, but oncology and specialty medicines provide the next growth pillars as Comirnaty and Paxlovid recede to 3% of revenue
Swipe to explore
Commercial-category and CentreOne revenues are reported; a $1M rounding source reconciles their displayed subtotals to consolidated revenue. The $862M net nonoperating expense is an arithmetic bridge where the statement displays $861M due rounding. The $9M NCI-and-rounding flow reconciles reported consolidated and parent income while the displayed NCI line is $8M.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Primary Care | 1 | $5.5B | 38.3% of revenue |
| Oncology | 1 | $3.8B | Ibrance, Padcev, Xtandi and more |
| Specialty Care | 1 | $2.9B | Led by Vyndaqel |
| Hospital & biosimilars | 1 | $1.9B | Sterile injectables and biosimilars |
| Pfizer CentreOne | 1 | $289M | Contract manufacturing |
| Portfolio rounding | 1 | $1M | Rounded category bridge |
| Revenue | 2 | $14.5B | Global medicines and vaccines |
| Earnings before net other items | 3 | $4.0B | Revenue less core operating costs |
| Products, R&D & commercial costs | 3 | $10.4B | Six reported operating-cost lines |
| Income before tax | 4 | $3.2B | 21.9% of revenue |
| Net nonoperating expense | 4 | $862M | Reported as $861M after rounding |
| Continuing-operations income | 5 | $2.7B | Before discontinued operations |
| Income tax | 5 | $461M | 14.6% effective rate |
| Consolidated net income | 6 | $2.7B | After discontinued operations |
| Discontinued-operations loss | 6 | $13M | Legacy disposed businesses |
| Pfizer net income | 7 | $2.7B | $0.47 diluted EPS |
| NCI & rounding | 7 | $9M | Displayed NCI line is $8M |
| From | To | Value |
|---|---|---|
| Primary Care | Revenue | $5.5B |
| Oncology | Revenue | $3.8B |
| Specialty Care | Revenue | $2.9B |
| Hospital & biosimilars | Revenue | $1.9B |
| Pfizer CentreOne | Revenue | $289M |
| Portfolio rounding | Revenue | $1M |
| Revenue | Earnings before net other items | $4.0B |
| Revenue | Products, R&D & commercial costs | $10.4B |
| Earnings before net other items | Income before tax | $3.2B |
| Earnings before net other items | Net nonoperating expense | $862M |
| Income before tax | Continuing-operations income | $2.7B |
| Income before tax | Income tax | $461M |
| Continuing-operations income | Consolidated net income | $2.7B |
| Continuing-operations income | Discontinued-operations loss | $13M |
| Consolidated net income | Pfizer net income | $2.7B |
| Consolidated net income | NCI & rounding | $9M |